mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer

Journal article

Over 50 % of patients with high-grade serous carcinoma (HGSC) are homologous recombination proficient, making them refractory to platinum-based drugs and poly (ADP-ribose) polymerase (PARP) inhibitors. These patients often develop progressive resistance within 6 months after primary treatment and tend to die early, thus new therapies are urgently needed. In this study, we comprehensively investigated this tumor type by leveraging a combination of machine learning analysis of a large published dataset and newly developed genetically engineered HGSC organoid models from murine fallopian tubes. Aberrant activation of RAS/PI3K signaling was a signature of poor prognosis in BRCA1/2 wild-type ovarian cancer, and mTOR-induced elevated p62 expression was a robust marker of chemotherapy-induced mTOR-p62-NRF2 signal activation. mTOR inhibition with everolimus decreased p62 and enhanced sensitivity to conventional chemotherapy, indicating that p62 serves as an important biomarker for therapeutic intervention. Combination therapy with conventional chemotherapy and mTOR inhibitors is a promising therapeutic strategy for refractory HGSC, with p62 as a biomarker.

Authors: Tamura, T; Nagai, S; Masuda, K; Imaeda, K; Sugihara, E

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Cancer Letters
• Volume: 616
• Article number: 217565
• Publication date: 2025-02-17
• Acceptance date: 2025-02-14
• DOI: 10.1016/j.canlet.2025.217565
• EISSN: 1872-7980
• ISSN: 0304-3835
• Language: English
• Keywords: ovarian cancer; p62/SQSTM1; mTOR inhibitor; BRCA1/2 wild type